Premium
Effects Of Triptolide On The Expression Of Inflammatory Markers In Lipopolysaccharide‐Treated Human Endothelial Cells (HUVEC)
Author(s) -
Galvez Gabriela,
Santander Stephanie,
Raskin Ilya,
Baldeon Manuel
Publication year - 2015
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.29.1_supplement.789.1
Subject(s) - triptolide , lipopolysaccharide , inflammation , tripterygium wilfordii , tumor necrosis factor alpha , flow cytometry , medicine , immunology , immune system , endothelium , pharmacology , apoptosis , chemistry , pathology , biochemistry , alternative medicine
Endothelium dysfunction is characterized by the abnormal expression of inflammatory genes observed in chronic pathologies like diabetes. Data shows that Triptolide from Tripterygium wilfordii Hook F, inhibits the expression of inflammatory markers blocking TLR‐4 signaling in immune cells . This study determined the effect of Triptolide on the expression of inflammatory related genes, nuclear factor HIF‐1α, and adhesion molecules ICAM‐1 and P‐selecting in HUVEC treated with lipopolysaccharide (LPS). Expression of IL‐1, IL‐6, TFN‐α, iNOS, and HIF‐1α was measured with qRT‐PCR while ICAM‐1 and P‐selecting expression was measured by flow‐cytometry. LPS treatment increased the expression of IL‐1, IL‐6, TFN‐α, iNOS, and ICAM‐I after 24 h of treatment. The increased expression of the indicated genes was decreased when cells were simultaneously treated with triptolide. The inhibitory effect excerpted by triptolide was dose dependent. Contrary, expression of HIF‐1α was not altered by LPS or Triptolide treatment but was increased when LPS and Triptolide were combined.Similar to the anti‐inflammatory effects of Triptolide treatment observed in LPS‐stimulated immune cells , Triptolide decreased the expression of inflammatory markers in human endothelial cells . The simultaneous treatment of LPS and Triptolide increased HIF‐1α expression without affecting the expression of other inflammatory markers. Data indicated that Triptolide treatment affected different pathways in HUVEC.Correction of endothelium dysfunction by Triptolide in inflammatory and chronic diseases could alter the progression of these pathologies.